Last updated: August 7, 2026
Fenofibric acid is a mature lipid-lowering active with limited value in basic molecule protection and greater opportunity in formulation engineering, supply-chain differentiation, and combination products. The strongest commercial strategies are lower-cost delayed-release capsules, food-independent oral delivery, sprinkle or alternative dosage forms, and fixed-dose combinations that improve adherence. Generic competition and the availability of fenofibrate products constrain pricing.
What is fenofibric acid and how is it marketed?
Fenofibric acid is the active metabolite of fenofibrate and a peroxisome proliferator-activated receptor alpha agonist. The branded product Trilipix is a delayed-release oral capsule available in 45 mg and 135 mg strengths. The product is indicated for hypertriglyceridemia, primary hypercholesterolemia or mixed dyslipidemia, and certain combination-treatment settings under its FDA label.[1]
| Attribute |
Fenofibric acid |
| Therapeutic class |
Fibrate lipid regulator |
| Active pharmacology |
PPAR-alpha agonism |
| Branded product |
Trilipix |
| Original sponsor |
Abbott Laboratories |
| Current commercial status |
Generic competition; mature product |
| Dosage form |
Delayed-release capsule |
| Label strengths |
45 mg and 135 mg |
| FDA approval |
Trilipix NDA approved in 2008 |
| Primary formulation issue |
Oral delivery of a poorly water-soluble lipid-regulating compound |
| Main commercial constraint |
Low-cost fenofibrate and generic fenofibric acid competition |
Trilipix uses a delayed-release design and may be administered without regard to meals, according to the prescribing information.[1] That attribute is commercially important because older fenofibrate formulations often had stronger food-effect and administration requirements.
How does fenofibric acid compare with fenofibrate?
Fenofibric acid and fenofibrate are closely related but commercially distinct products. Fenofibrate is converted in vivo to fenofibric acid. Fenofibric acid products avoid reliance on metabolic conversion, while fenofibrate has a larger generic product base and broader formulation history.
| Factor |
Fenofibric acid |
Fenofibrate |
| Active administered |
Fenofibric acid |
Fenofibrate |
| Typical formulation challenge |
Delayed release and dissolution control |
Poor aqueous solubility and food effect |
| Generic competition |
Present but narrower |
Broad and well established |
| Differentiation potential |
Release profile, combinations, administration convenience |
Nanoparticles, micronization, tablets, capsules, combinations |
| Regulatory positioning |
ANDA or 505(b)(2), depending on product |
ANDA, 505(b)(2), and multiple legacy formulations |
| Commercial pricing |
Generally pressured |
Highly commoditized |
The commercial case for a new fenofibric acid product must therefore be based on a measurable advantage rather than the active ingredient alone.
What excipients are used in fenofibric acid products?
Fenofibric acid delayed-release capsules generally use excipients for powder flow, capsule filling, mechanical integrity, lubrication, and release control. Product-specific inactive ingredients vary by manufacturer and should be confirmed against the FDA Inactive Ingredient Database and approved product labeling.[2,3]
Common excipient categories include:
| Excipient function |
Candidate materials |
Strategic purpose |
| Dilution and bulk |
Lactose monohydrate, microcrystalline cellulose |
Controls fill weight and improves manufacturing consistency |
| Disintegration |
Crospovidone, croscarmellose sodium |
Promotes capsule-content breakup after release |
| Lubrication |
Magnesium stearate |
Supports capsule filling and compression processes |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Surfactancy |
Sodium lauryl sulfate or alternative surfactants |
Improves wetting and dissolution |
| Film coating |
Hypromellose, hypromellose phthalate, methacrylate polymers |
Controls delayed release and protects drug particles |
| Opacification and color |
Titanium dioxide, iron oxides, approved colorants |
Supports identification and light protection |
| Enteric protection |
Methacrylic acid copolymers, hypromellose phthalate, cellulose acetate phthalate |
Delays release until intestinal pH conditions |
The most commercially relevant excipient choices are the wetting agent, particle or granule architecture, and enteric polymer. These components influence dissolution, release location, capsule stability, and manufacturing cost.
What formulation attributes matter most?
The target product profile should prioritize:
- Consistent release across physiologic pH conditions.
- Low sensitivity to food and gastric residence time.
- Adequate dissolution after intestinal release.
- Limited capsule-to-capsule variability.
- Stable performance under humidity and accelerated storage.
- Low excipient burden for patients with lactose, surfactant, or colorant concerns.
- Straightforward scale-up using conventional capsule-filling and coating equipment.
Fenofibric acid formulation development should not rely solely on increasing surfactant concentration. Excess surfactant can affect powder flow, capsule integrity, gastrointestinal tolerability, and stability. A controlled particle-size distribution combined with a suitable wetting system is usually more defensible than a high-excipient formulation with weak manufacturing margins.
What excipient strategy is commercially strongest?
The most attractive strategy is a multiparticulate delayed-release capsule using a controlled drug layer and enteric-coated particles. This architecture can separate release control from the capsule shell and may offer better pH performance than a simple coated powder blend.
Strategy 1: Enteric-coated multiparticulates
A multiparticulate capsule may contain pellets, granules, or mini-tablets with:
- A fenofibric acid-containing core.
- A seal coat to reduce drug-excipient interaction.
- An enteric polymer layer.
- Optional protective overcoat to improve handling and reduce tackiness.
This approach provides multiple release units and can reduce the consequences of dose-dumping from a single coated mass. It also creates potential intellectual-property positions around particle size, coating weight gain, polymer ratios, and dissolution profiles.
Strategy 2: Surfactant-assisted immediate release after intestinal delivery
An enteric-coated formulation can use a wetting agent or lipid-compatible carrier to improve post-release dissolution. Candidate systems include:
- Sodium lauryl sulfate at controlled concentration.
- Poloxamers.
- Polysorbates, subject to oxidation and peroxide control.
- Sodium docusate.
- Solubilizing polymer systems.
- Lipid-based carriers, if chemical and physical stability is demonstrated.
The commercial advantage is stronger if the formulation maintains exposure under fed and fasted conditions while using a lower total excipient load.
Strategy 3: Low-excipient or lactose-free formulation
A lactose-free product could address patients who avoid lactose and simplify product positioning for some contract-manufacturing channels. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, or starch-based systems may replace lactose, although each changes density, flow, moisture behavior, and dissolution.
This opportunity is commercially modest by itself. It becomes more valuable when combined with a smaller capsule, improved swallowability, or a formulation suitable for patients with dietary restrictions.
Strategy 4: Sprinkle or alternative administration
A sprinkle capsule containing enteric-coated multiparticulates could improve use by patients who have difficulty swallowing capsules. The critical requirement is that the pellets remain intact when mixed with an appropriate soft food or beverage and are not crushed or chewed.
This product would require careful labeling, dose-uniformity validation, moisture protection, and human-factors work. It could support a 505(b)(2) strategy if the administration method or product performance differs materially from the reference product.
Strategy 5: Fixed-dose combinations
Fenofibric acid has potential for combination products with agents used in mixed dyslipidemia, including statins. The principal commercial rationale is adherence, not a new mechanism.
Combination products face several barriers:
- Dose flexibility is lower than with separate products.
- Pharmacokinetic interaction must be characterized.
- Safety labeling must address both active ingredients.
- Prescribers may prefer titratable separate components.
- Combination patents can be vulnerable if they claim only routine coadministration.
A combination with a commonly prescribed statin may have greater commercial value than a stand-alone excipient improvement, but development cost and clinical positioning are higher.
What patents protect fenofibric acid formulations?
The original active-ingredient and delayed-release protection for Trilipix is no longer the principal commercial barrier. The current competitive assessment should focus on formulation, method-of-use, manufacturing, and combination patents rather than assuming broad residual exclusivity.
| Patent category |
Relevance to fenofibric acid |
Commercial strength |
| Active compound patents |
Limited for a mature active |
Low |
| Delayed-release composition patents |
May cover polymer systems, coating architecture, or dissolution |
Moderate if technically narrow and difficult to design around |
| Particle-size or solid-state patents |
May cover crystalline form, amorphous material, or particle distribution |
Moderate |
| Excipient-specific claims |
May cover defined ratios or functional combinations |
Low to moderate |
| Method-of-use patents |
May cover selected patient populations, combinations, or dosing schedules |
Variable |
| Manufacturing patents |
May protect coating, granulation, or scale-up processes |
Moderate where process is difficult to reproduce |
| Fixed-dose combination patents |
Can support lifecycle management |
Moderate, but vulnerable to obviousness attacks |
| Device or administration patents |
Relevant to sprinkle or novel delivery formats |
Moderate |
A defensible formulation patent should claim a measurable technical result, such as a defined dissolution profile, reduced food effect, improved stability, improved bioavailability, or manufacturing performance. Claims directed only to the selection of a conventional excipient are more exposed to obviousness and enablement challenges.
When does fenofibric acid lose exclusivity?
Trilipix received FDA approval in 2008, and its core commercial exclusivity has expired. Generic fenofibric acid delayed-release products are available, which confirms that the market is no longer protected by a broad branded monopoly.[2,4]
The practical exclusivity timeline is:
| Milestone |
Timing |
| Trilipix FDA approval |
2008 |
| Branded small-molecule exclusivity period |
Expired |
| Generic entry |
Occurred |
| Current competitive issue |
Formulation differentiation and cost |
| Future protection opportunity |
New formulation, combination, administration method, or manufacturing claims |
Patent expiration dates must be evaluated patent by patent through the FDA Orange Book and relevant national patent registers. A product-level statement that all fenofibric acid protection expires on one date would be inaccurate because formulation and method patents can have different terms, terminal disclaimers, and patent-term adjustments.[2]
What is the Orange Book status of fenofibric acid?
The FDA Orange Book lists approved drug products, reference products, patents, and exclusivity information. Trilipix is the reference product for fenofibric acid delayed-release capsules, while approved generic products can rely on an abbreviated pathway if they meet the applicable requirements.[2]
For a new entrant, the Orange Book review should address:
- Listed patents for the reference product.
- Whether patents remain active or have expired.
- Patent-use codes attached to method-of-use claims.
- ANDA certifications, including Paragraph IV certifications.
- Any 30-month stay associated with patent litigation.
- Whether the proposed labeling omits protected indications.
A new formulation may not be able to use a standard ANDA if it changes the dosage form, release mechanism, route of administration, or clinical performance. A 505(b)(2) application may be more appropriate where the sponsor relies partly on the listed drug but seeks approval for a modified formulation or administration method.[5]
Which companies are challenging fenofibric acid patents?
Generic competition is already established, but a reliable current list of Paragraph IV challengers requires a live review of FDA ANDA records, Orange Book certifications, and federal court dockets. Publicly visible competition is better assessed through approved ANDA products and active litigation than through historical patent challenges.
For business planning, the relevant challenger groups are:
- Established generic manufacturers with capsule-filling and enteric-coating capacity.
- Contract development and manufacturing organizations with multiparticulate platforms.
- Generic companies with fenofibrate portfolios.
- Specialty manufacturers pursuing sprinkle, pediatric, or adherence-oriented products.
The main litigation risk for a new fenofibric acid product is likely to involve formulation obviousness, claim construction, enablement, and bioequivalence rather than validity of the original active compound.
What generic launch risks exist for fenofibric acid?
Generic launch risk is high for a conventional delayed-release capsule. A competing product with the same strength, route, and release design can compete primarily on price, supply reliability, wholesaler access, and formulary status.
High-risk product profile
A product is especially exposed when it has:
- The same 45 mg and 135 mg strengths.
- Conventional hard capsules.
- No meaningful administration advantage.
- No differentiated label.
- A formulation based on widely used excipients.
- Manufacturing dependent on a single coating or API supplier.
- No enforceable formulation or process patents.
Lower-risk product profile
Risk is lower when the product has:
- A validated sprinkle administration method.
- A materially improved food-effect profile.
- A clinically relevant reduction in dosing frequency.
- A fixed-dose combination with a strong adherence rationale.
- A protected multiparticulate platform.
- A reliable supply advantage.
- A formulation that solves a known stability or dissolution problem.
The product must still demonstrate that the differentiation matters to payers, prescribers, or patients. Technical novelty without a reimbursement or adherence benefit will rarely support premium pricing.
What FDA regulatory pathways apply to new fenofibric acid formulations?
An ANDA is the lowest-cost regulatory route when the proposed product is pharmaceutically equivalent and bioequivalent to the reference listed drug. Differences in inactive ingredients may be acceptable if they do not affect safety, efficacy, or performance and are supported by the application.[5]
A 505(b)(2) application may be appropriate for:
- Sprinkle capsules.
- A new modified-release system.
- A different dosage form.
- A new strength or dosing regimen.
- A fixed-dose combination.
- A product with a new administration method.
The key regulatory package will typically include:
- Comparative dissolution across relevant pH conditions.
- Stability under long-term and accelerated conditions.
- In vitro release and dose uniformity.
- Bioequivalence or comparative pharmacokinetic studies.
- Food-effect evaluation where the formulation changes food sensitivity.
- Extractables and leachables for new packaging.
- Excipient qualification and justification.
- Manufacturing-process validation.
- Labeling support for any new administration instructions.
FDA guidance emphasizes that modified-release products require careful control of dissolution and in vivo performance because apparently minor formulation differences can affect exposure.[6]
How strong is the patent estate for fenofibric acid?
The patent estate is weak for a plain generic copy and potentially moderate for a technically differentiated formulation. The most valuable claims are likely to be narrow, evidence-based claims directed to:
- Defined enteric coating composition.
- Controlled particle-size distribution.
- Specific dissolution windows.
- Reduced fed-versus-fasted exposure variability.
- Improved stability under high humidity.
- Sprinkle administration with intact multiparticulates.
- A fixed-dose combination with defined pharmacokinetic or clinical performance.
Weak claim types include broad claims to fenofibric acid plus a conventional filler, lubricant, or enteric polymer without a demonstrated unexpected result.
Freedom-to-operate analysis should cover the United States, European Union, Japan, Canada, China, and major emerging markets. Patent term, prosecution history, national-phase status, and claim scope will differ by jurisdiction. Manufacturing patents may matter even where product patents have expired, especially if a supplier uses a protected coating or granulation process.
What licensing deals and commercial partnerships are relevant?
Fenofibric acid has greater partnership value as a platform component than as a standalone branded molecule. Potential deal structures include:
| Partnership model |
Commercial rationale |
| Formulation license |
Transfers a delayed-release or multiparticulate platform |
| Regional commercialization license |
Provides market access without building a sales force |
| Generic supply agreement |
Secures API or finished-dose capacity |
| Fixed-dose combination collaboration |
Shares development and regulatory risk |
| CDMO development agreement |
Accelerates coating, scale-up, and validation |
| Specialty-pharmacy partnership |
Supports sprinkle or adherence-focused positioning |
A licensing transaction is more defensible when the licensor controls issued formulation claims, validated manufacturing know-how, or a differentiated regulatory pathway. A license covering only routine excipients is unlikely to justify substantial upfront consideration.
What revenue exposure and market opportunities exist?
Revenue exposure is concentrated in price-sensitive chronic dyslipidemia markets. The original branded product has limited ability to sustain premium pricing against generic fenofibric acid and fenofibrate.
The most credible commercial opportunities are:
- A low-cost, reliable generic with strong supply performance.
- A lower-pill-burden fixed-dose combination.
- A sprinkle product for patients with swallowing difficulty.
- A formulation that minimizes food restrictions.
- A private-label or regional product supported by a low-cost CDMO.
- A differentiated product for markets where fenofibric acid availability is limited.
The opportunity is less attractive for a premium product that merely changes capsule color, filler, or lubricant. Payers generally require a measurable clinical, adherence, or utilization benefit before accepting a higher price.
Key Takeaways
- Fenofibric acid is a mature active with expired core exclusivity and established generic competition.
- Excipient value is concentrated in delayed release, intestinal dissolution, stability, and administration convenience.
- Multiparticulate enteric-coated capsules offer the strongest formulation and patent strategy.
- A lactose-free or low-excipient product may support differentiation but is unlikely to justify a major premium alone.
- Sprinkle capsules and fixed-dose combinations offer greater lifecycle value than routine excipient substitution.
- ANDA is appropriate for a close generic equivalent; 505(b)(2) may be required for materially modified products.
- Formulation patents should claim measurable performance, not merely conventional excipient selection.
- Manufacturing know-how, coating capability, and API supply reliability can be as important as patent scope.
- Generic launch risk is high for a conventional 45 mg or 135 mg delayed-release capsule.
- The strongest commercial case combines regulatory differentiation, enforceable formulation claims, and a clear patient or payer benefit.
FAQs
Is fenofibric acid more commercially attractive than fenofibrate?
Usually not as a standalone generic. Fenofibrate has a larger market and broader formulation base, while fenofibric acid may offer targeted opportunities in delayed-release, combination, and administration-convenience products.
Can a new fenofibric acid formulation receive patent protection?
Yes, if it demonstrates a novel and non-obvious formulation, release profile, administration method, combination, or manufacturing process. A conventional filler or enteric polymer substitution is less likely to produce strong protection.
Are excipient changes enough to require a 505(b)(2) application?
Not necessarily. Excipient changes can remain within an ANDA when the product remains pharmaceutically equivalent and bioequivalent. A 505(b)(2) pathway becomes more relevant when the change creates a new dosage form, release profile, administration method, or clinical use.
What is the best excipient for fenofibric acid dissolution?
No single excipient is universally optimal. A controlled wetting system combined with particle engineering and an enteric polymer is more commercially defensible than relying on one surfactant at a high concentration.
Can fenofibric acid support a pediatric or sprinkle product?
Potentially. A sprinkle product could address swallowing difficulty, but it would require evidence that the multiparticulates remain intact, provide dose uniformity, preserve delayed release, and remain bioequivalent or clinically appropriate under the proposed administration conditions.
References
-
U.S. Food and Drug Administration. (2008). Trilipix (fenofibric acid) delayed-release capsules prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
-
U.S. National Library of Medicine. (n.d.). Fenofibric acid delayed-release capsule product labeling. DailyMed.
-
U.S. Food and Drug Administration. (2022). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
-
U.S. Food and Drug Administration. (2019). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. FDA.
